ROZLYTREK is indicated for the treatment of adults with solid tumors that:• have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation,• are metastatic or where surgical resection is likely to result in severe morbidity, and• have either progressed following treatment or have no satisfactory alternative therapy.ROZLYTREK is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.